All In Biotech

Free tool

FAERS Monitor: Ryzumvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217064 or its brand name (Ryzumvi, Phentolamine Mesylate). Reports on generic versions are filed under their own applications.

Reports

139

Serious

91

65% of reports

Hospitalization

44

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ocular hyperaemia20
  • blood urea increased14
  • blood glucose increased13
  • neutrophil count increased13
  • anaemia12
  • diarrhoea12
  • headache12
  • hypertension12
  • lymphocyte count decreased12
  • drug ineffective11
  • dizziness10
  • haemoglobin decreased10
  • abdominal distension9
  • blood pressure increased9
  • eye pain9

Reports by year received

View as table
YearReports
20042
20052
20076
20081
20093
20102
201115
20125
20141
20152
20164
201715
20184
20194
20203
20215
20224
20233
202420
202526
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,020 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neutrophil count increasedSignal13192.4114.62,285
blood urea increasedSignal14126.777.11,622
lymphocyte count decreasedSignal12102.859.81,110
ocular hyperaemiaSignal2063.842.51,176
eye painSignal924.112.8178
haemoglobin decreasedSignal1014.78.1115
abdominal distensionSignal913.06.989
blood glucose increasedSignal1310.46.2103
anaemiaSignal129.55.584
blood pressure increasedSignal98.94.756
hypertensionSignal128.65.074
dizzinessSignal103.01.712
headacheSignal122.91.713
diarrhoeaSignal122.81.613
drug ineffective111.30.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.